Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292912 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04292912 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT04292912, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
Interventions
- DRUG GSK2798745
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-09-07 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04292912
The ClinicalTrials.gov registry entry for NCT04292912 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK2798745 is the first listed.
NCT04292912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04292912 about?
NCT04292912 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema". The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
What is the current status of trial NCT04292912?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-09-07. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT04292912?
The interventions under investigation include: GSK2798745 (DRUG).
Who is sponsoring clinical trial NCT04292912?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.